Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Aug 7, 2017
Generic Drug Price Deflation Continues to Weigh on Shares of Teva
Shares of former Best Ideas Newsletter portfolio idea Teva Pharmaceuticals have come under renewed selling pressure after reporting weak quarterly results due largely to deflationary price pressures felt in the generic drug division. Teva has been relatively powerless in stopping the trend. We had removed the shares from the Best Ideas Newsletter portfolio well before the last leg down, and the Dividend Cushion ratio warned of tremendous risk to the sustainability of the dividend far in advance. Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer… Aug 13, 2015
Big Pharma Earnings Continued…
Amgen, AstraZeneca, Merck, and Pfizer... Feb 5, 2015
Some Wiggle Room, Please
Lots of earnings reports out. Let’s go around the horn. Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings. Jan 27, 2014
Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space . Jun 20, 2013
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Big Pharma is not dead, but neither are the generics. Let’s take a look at opportunities presented from patent expiry in the US and low generic utilization rates across the globe. We don’t think investors are expecting the “mountain” of opportunities in 2015. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
